The New Cannabis & CBD Therapy for PTSD

This podcast is part of our StockTalk Cannabis Sector CEO interview series, and our mission going forward is to help listeners and investors understand more about investment opportunities in the public cannabis marketplace. 

There are around eight million people in the U-S who suffer from symptoms related to Post-Traumatic Stress Disorder. Although some cognitive therapies have proven to be helpful, there are no pharmaceutical drugs that target this condition. PTSD is a disorder that not only affects the individual, but also their family and community. 

Allied Corp. (OTCQB:ALID, Forum) is an international cannabis Company with a mission to help people suffering from PTSD by researching, creating and producing targeted cannabinoid health solutions. 

Trading on the O-T-C-Q-B Venture Market under the ticker A-L-I-D, the Company uses an evidence-informed scientific approach to make this mission possible. Through cutting-edge pharmaceutical research and development, Allied Corp also deploys innovative plant-based production, along with unique development of therapeutic products. 

The Company also recently launched its Tactical Relief e-commerce platform, hailed as a major step forward in its’s digital strategy, which remains on-track for full global roll-out within Q4 2019. 

Stockhouse was joined by the Company’s Chief Executive Officer, Calum Hughes to learn more about Allied’s vision.